Ardy Arianpour

CEO & Co-Founder @SEQSTER | Health Data Is Medicine ™ | Digital Health & Clinical Trials Innovator | Speaker

Patient-centric data interoperability is healthcare’s biggest challenge and my #1 mission. That is why I founded SEQSTER, the leading healthcare technology company that has pioneered the ability to break down health data silos at scale. Our enterprise operating system aggregates disparate health data sources into a single, 360-degree longitudinal patient record in real-time, solving a multitude of challenges for Life Sciences, Patient Engagement and Data Interoperability.

I am a visionary health tech pioneer and serial entrepreneur with two decades of experience harnessing technology to solve some of healthcare’s biggest challenges. Innovation is meaningless without execution. At Seqster we have worked with global pharma and digital health leaders to transform healthcare to meet the rapidly growing and changing needs of patients and researchers.

My path was not always healthcare. At 18, I was labeled an “investment prodigy” by the Chicago Tribune and landed in the national spotlight with coverage in TIME’s first story on online investing in 1998. I was then heavily influenced by my experience with the cutting-edge research at the Salk Institute working in the lab of Lasker Award winner Dr. Ron Evans. From there, I established a reputation for innovation and execution at a pair of high-profile California companies: Ambry Genetics (sold to Konica for $1B) and Pathway Genomics. As Senior Vice President of business development at Ambry, I built the genomics services division and launched the first commercial clinical exome sequencing test for diagnostic odysseys, establishing the value of next-generation sequencing in the clinic. My team was also instrumental in driving the launch of Ambry’s BRCA test following the landmark SCOTUS decision in 2013 that scrapped gene patents, rapidly expanding genetic testing access for breast cancer patients and family members across the country.

As Chief Strategy Officer at Pathway Genomics, I introduced Pathway’s BRCATrue gene test to the market, established the BRCA One-for-One program in conjunction with the Susan G. Komen Foundation, and helped provide ~$10 million in free testing for persons in need.

I received my BS in Biological Sciences from UC Irvine and my MBA from Marshall Goldsmith School of Management. And, I am honored to have been named a Medical, Marketing, and Media’s (MM&M) Top 40 Healthcare Transformer, San Diego Business Journal 40 under 40, Top Tech Awardee, SD500 Most Influential Leaders and Top 10 Pioneers Redefining Healthcare in 2021.